No Picture
Stocks List

Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) is a worldwide biopharmaceutical organization essentially centered around the innovative work (R&D) of medications. Its principle item, AMITIZA, is the main chloride channel activator produced for the treatment of endless blockage. It may not be the sexiest item, but rather the best medications once in a while are.

Since 2006, AMITIZA, otherwise called lubiprostone, has been administered more than 10 million times. As of now, it is accessible as a little oral gelcap taken twice per day and is endorsed for three signs that spread unmistakable patient sorts: unending idiopathic obstruction (CIC), fractious inside

Read More
No Picture
Stocks List

Skyline (NASDAQ:SKLN)

Skyline (NASDAQ:SKLN)

Skyline (NASDAQ:SKLN) recently reported \that it was expanding its unit trade offering. This offering from January permits financial specialists who acquired the more established, August 2015, units to trade those units for recently offered units.

In August, Skyline raised $19M by offering 1,666,667 units with every unit comprising of one offer of normal stock, one Series B convertible offer and four Series A warrants. The Series A warrants are exercisable at $4.95/share furthermore incorporated a “cashless” change highlight.

The more up to date units’ Series B warrants had generously comparative components to the old Series A warrants however

Read More
No Picture
Stocks List

Provectus Biopharmaceuticals (PVCT)

Provectus Biopharmaceuticals (PVCT)

Meagerly exchanged nano cap Provectus Biopharmaceuticals (PVCT) droops on a 4x surge in volume in light of the evaluating of its “earnest attempts” public equity offering.

The organization is putting forth 240K shares of Series B Convertible Preferred Stock, at first convertible into a total of 24M shares of regular stock, and warrants to buy up to 24M shares of basic at a cost of $25 for a blend of one Series B offer and one quickly exercisable five-year warrant to buy one offer of basic at $0.275.

In the event that effective, gross proceeds will be

Read More
No Picture
Penny Stocks Articles

Progenics (NASDAQ:PGNX)

Progenics (NASDAQ:PGNX)

Progenics (NASDAQ:PGNX) reported Q2 EPS and incomes in front of perspectives, and it was not because of superior to anything expected Relistor sovereignties. The organization perceived a $4 million point of reference installment from Bayer (OTCPK:BAYRY) for the PSMA Antibody Technology permit. This cooperation could open some shareholder esteem in the next years. News broke a week ago that Relistor is drawing some purchaser interest and that Valeant (NYSE:VRX) may offer its rights to the most noteworthy bidder.

A $400-500 million sticker price was specified in the Bloomberg article. The inferred cost allots little esteem to Relistor considering

Read More
No Picture
Stocks List

Pieris Pharmaceuticals Inc. (PIRS:NASDAQ)

Pieris Pharmaceuticals Inc. (PIRS:NASDAQ)

Pieris Pharmaceuticals Inc. (PIRS:NASDAQ) was initially a German-based organization emerging from exploration done on some novel proteins. They framed in 2001, and have stretched into numerous sickness signs: oncology, iron deficiency, asthma, ophthalmology, and irresistible illness.

Coming from Technical University of Munich (TUM) through Dr. Arne Skerra’s work, Pieris was conceived. They are as of now transitioning into a move to be headquartered in the U.S. from Germany. We’ll go into this later, however we trust this is to stay away from rivalry in Europe.

With a business sector top of simply over $65 million USD,

Read More
No Picture
Stocks List

Pain Therapeutics is a Solid Pick in Biotech Industry

Pain Therapeutics is a Solid Pick in Biotech Industry

Pain Therapeutics is working in the biotech and pharmaceutical industry, having a business sector capitalization of $116.69 million. Opioid misuse is a developing pestilence, and the weight is on to grow better manhandle impediment definitions. Torment Therapeutics is creating two such items, one oral and the other a patch.

The present share price is $2.55, which places it in penny stock domain (under $5.00). In this manner, the dangers connected with penny stocks and low market capitalizations ought to be considered. Financial specialists who comprehend the dangers ought to consider this

Read More
No Picture
Stocks List

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)

It’s been an unpleasant year for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) shareholders. PPHM slammed on 2/26/2016 when the organization’s Phase III trial for Bavituximab (an exploratory hostile to malignancy medication) was ended. Be that as it may, things were not all fate and unhappiness. Another bio-producing office was commisioned on 3/17/2016. While Bavituximab may have hit a deadlock, the Avid Bioservices division is blasting. The new plant dramatically increased Avid’s assembling limit.

The uplifting news for the Avid Bioservices division proceeded with financial Q4 2016 results. Devoted reported a $68 million income overabundance. Fabricating incomes of $50

Read More
No Picture
Stocks List

Palatin Technologies Inc. (PTN)

Palatin Technologies Inc. (PTN)

Palatin Technologies Inc. (PTN ) has been moving recently as the stock has ascended by 19% in the previous four weeks, and it is as of now exchanging great over its 20-Day SMA. This is a really strong move higher, yet the inquiry that must be on speculators’ brains at this moment is; would this be able to pattern proceed?

While there can be no telling without a doubt, it is unquestionably reassuring that profit gauges have ascended in the previous couple of weeks on the organization, proposing that estimation on PTN is moving in the

Read More
No Picture
Stocks List

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

An oral insulin tablet could tackle, however for a long time, no organization has made sense of how to even hypothetically regulate insulin orally. That is, as of recently. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has demonstrated on a basic level through a late Phase II concentrate on that insulin can be taken orally in the right plan, and lowers evening time pooled glucose contrasted and fake treatment, at any rate as indicated by one trial.

A bigger Phase III study will need to affirm these discoveries and is at present being arranged, however the essential confirmation is

Read More
No Picture
Stocks List

Northwest Biotherapeutics (NWBO)

Northwest Biotherapeutics (NWBO)

Following a decline of 9.3% amid Northwest Biotherapeutics (NWBO) facilitates all things considered volume in light of its revelation that it reduced the activity costs for certain warrant holders as an instigation to bring ~$1.3M up in new capital.

The organization offered an activity cost of $0.35 an offer for warrants to buy up to 3,656,817 shares of normal stock with unique activity costs of $4.50 – 6.00.

What’s more, Northwest issued new five-year Series E Warrants to the same warrant holders to buy up to 3,656,817 shares of basic stock at $0.41 an offer.

However, the

Read More
No Picture
Penny Stocks Articles

Neuralstem, Inc. (Nasdaq:CUR)

Neuralstem, Inc. (Nasdaq:CUR)

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical organization concentrated on the advancement of focal sensory system treatments in light of its neural undifferentiated organism innovation, reported its money related results and gave business and clinical overhauls to the three and six months time spans finished June 30, 2016.

In the second quarter of 2016, the organization have taken measures to enhance the Company’s cost structure and finished activities to fortify the association, especially with the arrangement of another Scientific Policy Committee.

In Q2, the organization carried clinical headways with its lead compound, NSI-189, and they are satisfied with movement

Read More
No Picture
Stocks List

MiMedx Group Inc (MDXG)

MiMedx Group Inc (MDXG)

MiMedx Group Inc (MDXG) shares exchanged higher after the organization reported strong growth in its second quarter and increased its full year guidance.

The organization said that in light of the quarter-to-date comes about, it sees income between $62 million and $64 million for the second from last quarter. Examiners gauge $63.12 million income. The organization communicated the certainty that the new item dispatches like OrthoFlo would empower it to accomplish the upper end of the income estimate.

For the entire year, MiMedx emphasized its direction of $243.5–$248 million with final quarter income to be exceptionally

Read More
No Picture
Stocks List

Neovasc Inc. (NVCN)

Neovasc Inc. (NVCN)

Starting late, it has certainly been an incredible time to be a financial specialist in Neovasc Inc. (NVCN). The stock has moved higher by 29% in the previous month, while it is likewise over its 20 Day SMA as well. This blend of solid value execution and ideal specialized, could recommend that the stock might be on the right way.

Exercises to build the rate of enrolment of patients in the Tiara clinical system, including new focuses, presenting the 40 mm Tiara and refining incorporation criteria are bringing about an expanded number of implantations. There have now

Read More
No Picture
Stocks List

Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals, Inc. (MRNS ) was a major mover recently, as its shares ascended more than 29%. The move went ahead strong volume too with significantly a greater number of shares changing hands than in an ordinary session. Recent rally proceeds with the late uptrend for the organization, as the stock is currently up more than 55% in the previous one-month time period.

Marinus Pharmaceuticals has been on somewhat of an icy streak of late, however there may be promising end to present circumstances for this ignored stock. What’s more, for specialized financial specialists there is

Read More
No Picture
Stocks List

Mast Therapeutics (NYSEMKT:MSTX)

Mast Therapeutics (NYSEMKT:MSTX)

Mast Therapeutics (NYSEMKT:MSTX) says stage 3 EPIC trial of vepoloxamer, which treats people with sickle cell illness encountering vaso-occlusive emergency, did not meet its essential adequacy endpoint.

Endpoint was measurably huge diminishment in the mean length of VOC (82 hours in the vepoloxamer bunch contrasted with 78 hours in the fake treatment bunch in the plan to-treat populace (p=0.09)). There were no measurably critical contrasts between treatment bunches in the goal to-treat populace over the two optional viability endpoints, rate of re-hospitalization for VOC and the event of intense mid-section disorder.

The Company’s CEO said “We are

Read More
No Picture
Stocks List

Is Aurinia’s Share Price Undervalued?

Is Aurinia’s Share Price Undervalued?

On August 16, 2016, Aurinia’s share price had dove in spite of its Phase 2B study meeting the essential endpoints in the treatment of Lupus Nephritis with Aurinia’s lead drug voclosporin.

Analysts was entirely shocked by the negative response to Aurinia’s stock price after the discharge on August 15 of the exceptionally positive Phase 2B top line information from the twofold visually impaired 265 patient AURA investigation of voclosporin in the treatment of Lupus Nephritis (“LN”). The essential endpoints in the study were met, and analysts anticipated that the stock price would physically increment (not

Read More
No Picture
Stocks List

IMMUNOMEDICS, INC. (IMMU)

IMMUNOMEDICS, INC. (IMMU)

IMMUNOMEDICS, INC. (IMMU) got agreement suggestion of “Beat” from Analysts surveyed at Thomson Reuters. The Company anticipated that would declare next income roughly $-0.13 for each share.

One Month Ago Analyst Ratings: The Company has gotten mean Analyst rating of 2.00 from surveyed investigators at Reuters One Month Ago. It has been recommended as “Purchase Opinions” from 1 and 0 issued “Offer Thoughts” for the stock. 1 evaluated the organization as a “Hold”. “Beat View” rating was uncovered by 0 and “Fail to meet expectations Signal” rating was issued by 0.

Deals Estimates: Wall Street Analysts are

Read More
No Picture
Stocks List

ImmunoCellular (IMUC)

ImmunoCellular (IMUC)

ImmunoCellular (IMUC) has gained ground in the main portion of this current year, and the organization says that 2016 will be a year of achievement for its organization. The main patient in the ICT-107 stage 3 trial was dealt with in June – a noteworthy accomplishment for its organization. Today, more than 140 patients have been screened and clinical site enactment is quickening.

The organization presently have initiated 60 clinical destinations in the US, two in Canada, and one in the UK, with more anticipated that would come in the second from last quarter. With ICT-107, ImmunoCellular is

Read More
No Picture
Stocks List

JA Solar (NASDAQJASO)

JA Solar (NASDAQJASO)

JA Solar Is Tumbling

JA Solar (NASDAQ:JASO) stock has plunged from over $10 a year ago to underneath $6 this year. Today, it is exchanging underneath $6.40.

The fall has made extremely appealing a buyout offer of $9.69 per share made by its Chairman and CEO Baofang Jin last June. At a stock cost of $6.40, this would speak to a premium of more than 51%.

In the event that JA Solar signs a “conclusive assention,” as Trina Solar (NYSE:TSL) did as of late, to go private, JA Solar stock may hole up promptly to over $8.60

Read More
No Picture
Stocks List

JinkoSolar Holding Co., Ltd. (NYSEJKS)

JinkoSolar Holding Co., Ltd. (NYSEJKS)

Will JinkoSolar Holding Makes a Rebound?

Shares of solar oriented maker JinkoSolar Holding Co., Ltd. (NYSE:JKS) dropped 14.4% in September as solar oriented stocks dropped no matter how you look at it.

The awful news amid the month for sun oriented makers was that sun based board costs have kept on diving in the second 50% of 2016. Board costs are currently at or beneath $0.40 per watt on the spot showcase, a level that would leave next to no edge or potentially of benefit for producers like JinkoSolar.

Consider that JinkoSolar produced net income

Read More